SCHEMBL9744348

SCHEMBL9744348

CC(C)c1c(O)cc(O)cc1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 1/20 0.48
TDP1 Q9NUW8 1/20 0.42
MEN1 O00255 2/20 0.40
CYP3A4 P08684 2/20 0.40
KMT2A Q03164 2/20 0.40
HPGD P15428 1/20 0.40
EGFR P00533 2/20 0.39
CDK4 P11802 2/20 0.39
CCND1 P24385 2/20 0.39
BACE1 P56817 1/20 0.39
BCL2 P10415 1/20 0.38
BCL2L1 Q07817 1/20 0.38
MCL1 Q07820 1/20 0.38
BCL2L2 Q92843 1/20 0.38
NQO1 P15559 1/20 0.38
ALDH1A1 P00352 2/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
PTGS1 P23219 2/20 0.36
TRPA1 O75762 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29427938 0.85 CYP3A4 (0.43) AHRTDP1MEN1CYP3A4KMT2A
SCHEMBL16010550 0.85 CYP3A4 (0.43) AHRTDP1MEN1CYP3A4KMT2A
SCHEMBL17402434 0.83 AHR (0.37) AHRTDP1MEN1CYP3A4KMT2A
SCHEMBL1494319 0.80 SELL (0.52) AHRTDP1KMT2ABCL2BCL2L1
SCHEMBL7528889 0.80 GABRA1 (0.56) AHRTDP1CYP3A4KMT2AHPGD
SCHEMBL2979291 0.80 EGFR (0.50) TDP1MEN1CYP3A4KMT2AHPGD
SCHEMBL919649 0.79 AHR (0.67) AHRTDP1MEN1CYP3A4KMT2A
SCHEMBL919650 0.79 AHR (0.67) AHRTDP1MEN1CYP3A4KMT2A
SCHEMBL24227147 0.78 TDP1 (0.39) AHRTDP1MEN1CYP3A4KMT2A
SCHEMBL9745420 0.78 GABRA1 (0.52) AHRTDP1CYP3A4HPGDBCL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250090554-A1 A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION MYND LIFE SCIENCES INC (CA) 2025-03-20 US disclosed
EP-4004080-B1 POLY(ARYLENE ETHER) COMPOSITIONS SHPP GLOBAL TECH BV (NL) 2023-08-16 EP disclosed
US-20230145822-A1 SMALL MOLECULES INDUCING THE DEGRADATION OF THE CELLULAR PRION PROTEIN FONDAZIONE TELETHON (IT) 2023-05-11 US disclosed
US-20230145822-A1 SMALL MOLECULES INDUCING THE DEGRADATION OF THE CELLULAR PRION PROTEIN FONDAZIONE TELETHON (IT) 2023-05-11 US disclosed
EP-4169958-A1 LINEAR BLOCK COPOLYMER AND CURABLE THERMOSETTING COMPOSITION COMPRISING THE LINEAR BLOCK COPOLYMER SHPP Global Technologies B.V. (NL) 2023-04-26 EP disclosed
US-11505528-B2 Inhibitors of microbially induced amyloid AXIAL THERAPEUTICS, INC. (US) 2022-11-22 US disclosed
WO-2022098879-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME AXIAL THERAPEUTICS, INC. (US) 2022-05-12 WO disclosed
US-20220133634-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME AXIAL THERAPEUTICS, INC. (US) 2022-05-05 US disclosed
EP-3134421-B1 NEW LIPOPHENOL COMPOUNDS AND USES THEREOF INST NAT SANTE RECH MED (FR) 2022-04-20 EP disclosed
US-11236082-B2 EZH2 inhibitors and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-01 US disclosed
US-20150133678-A1 ORGANIC COMPOUNDS CONTAINING SQUARIC ACID OR CROCONIC ACID MOIETIES FOR APPLICATION IN ELECTRONIC DEVICES SONY CORPORATION (JP) 2015-05-14 US disclosed
US-8946188-B2 Anti-microbial agents and uses thereof SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2015-02-03 US disclosed
US-8716344-B2 Class- and isoform-specific HDAC inhibitors and uses thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2014-05-06 US disclosed
US-20140024611-A1 ANTI-MICROBIAL AGENTS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-01-23 US disclosed
US-8461128-B2 Anti-microbial agents and uses thereof SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2013-06-11 US disclosed
US-20120208889-A1 CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUE, INC. (US) 2012-08-16 US disclosed
US-20120208889-A1 CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUE, INC. (US) 2012-08-16 US disclosed
US-20090170805-A1 ANTI-MICROBIAL AGENTS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-07-02 US disclosed
US-5087548-A POSITIVE TYPE RADIATION-SENSITIVE RESIN COMPOSITION JAPAN SYNTHETIC RUBBER CO., INC. (JP) 1992-02-11 US disclosed
EP-0227487-A2 Positive type radiation-sensitive resin composition JAPAN SYNTHETIC RUBBER CO., LTD. (JP) 1987-07-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11505528-B2 Inhibitors of microbially induced amyloid SNCA, PARK7, PRNP AHR 1997/4885TDP1 452/4885MEN1 4376/4885
US-20140024611-A1 ANTI-MICROBIAL AGENTS AND USES THEREOF ACAT1, ACAT2, APEH AHR 1296/4885TDP1 4413/4885MEN1 4155/4885
US-20120208889-A1 CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF HDAC1, HDAC5, HDAC6 AHR 1488/4885TDP1 2992/4885MEN1 4444/4885
US-20220133634-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME APC, SNCA, PARK7 AHR 60/4885TDP1 1631/4885MEN1 3511/4885
US-20090170805-A1 ANTI-MICROBIAL AGENTS AND USES THEREOF ACAT1, ACAT2, APEH AHR 1296/4885TDP1 4413/4885MEN1 4155/4885
US-20150133678-A1 ORGANIC COMPOUNDS CONTAINING SQUARIC ACID OR CROCONIC ACID MOIETIES FOR APPLICATION IN ELECTRONIC DEVICES SQLE, ACSL1, ACSL3 AHR 533/4885TDP1 4680/4885MEN1 4310/4885
US-11236082-B2 EZH2 inhibitors and uses thereof EZH2, EZH1, BMI1 AHR 2744/4885TDP1 2226/4885MEN1 1860/4885
US-20230145822-A1 SMALL MOLECULES INDUCING THE DEGRADATION OF THE CELLULAR PRION PROTEIN PRNP, PPIE, PPIC AHR 3054/4885TDP1 1059/4885MEN1 3669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.